CytomX Therapeutics : View Presentation

CytomX 2023 Priorities and Pipeline Update

January 5, 2023

Forward-Looking Statements

This presentation may contain projections and other forward-looking statements regarding future events. All statements other than statements of historical facts contained in this presentation, including statements regarding our future financial condition, technology platform, development strategy, prospective products, preclinical and clinical pipeline and milestones, regulatory objectives, expected payments from and outcomes of collaborations, and likelihood of success, are forward-looking statements. Such statements are predictions only and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, among others, the costs, timing and results of preclinical studies and clinical trials and other development activities; the uncertainties inherent in the initiation and enrollment of clinical trials; the uncertainties associated with the COVD-19 pandemic; expectations of expanding on-going clinical trials; availability and timing of data from clinical trials; the unpredictability of the duration and results of regulatory review; market acceptance for approved products and innovative therapeutic treatments; competition; the potential not to receive partnership milestone, profit sharing or royalty payments; the possible impairment of or inability to obtain intellectual property rights; and possible safety or efficacy concerns, general business, financial and accounting risks and litigation. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. More information concerning us and such risks and uncertainties is available on our website and in our press releases and in our public filings with the U.S. Securities and Exchange Commission. We are providing this information as of its date and do not undertake any obligation to update or revise it, whether as a result of new information, future events or circumstances or otherwise. Additional information may be available in press releases or other public announcements and public filings made after the date of this presentation.

This presentation concerns products that have not yet been approved for marketing by the U.S. Food and Drug Administration (FDA). No representation is made as to their safety or effectiveness for the purposes for which they are being investigated.

2

Agenda

Introduction

Moderna Collaboration

CX-2029 Phase 2 Cohort Expansion Data Update

Expanding R&D Activities in T-cell engaging bispecifics

• CX-904(EGFRxCD3) Phase 1 Progress
• Astellas Collaboration
• Regeneron Collaboration

2023 Potential Events and Milestones

Q&A

3

The Promise of Conditionally Active, Localized Biologic Therapies

R&D Challenge

• Next Generation Biologic Therapies have evolved to highly potent formats including:
• • T-CellEngagers (TCBs)
  • Antibody Drug Conjugates (ADCs)
  • Immunotherapies
• Separating potency from toxicity is a key challenge for optimizing therapeutic effectiveness

CytomX Probody® Therapeutics

• Designed to localize anti-cancer efficacy and decrease systemic toxicities

tumor

Active Antibody

Masked Probody Tx

4

Integrated Business Model for Long-Term Value Creation

Leader in localized biologic therapies

Multi-Modality Platform

$194M Cash as of Q3 2022

Broad IP portfolio

Probody® Platform

Robust

Financing

and IP

Deep Pipeline

Strong Partners

4 Clinical-stage assets

2 INDs expected in 2023

6 major partnerships

4 molecules in the clinic

5